| Latest Oxford Biomedica News Headlines |
| Date | Time | Source | |
| 08/27/2008 | 11:33AM | UKREG | Notice of Interim Results
RNS Number : 1493C
Oxford Biomedica PLC
27 August 2008
FOR IMMEDIATE RELEASE 27 AUGUST 2008
OXFORD BIOMEDICA PLC
NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2008
Oxford, UK - 27 August 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces... More...>> |
| 08/22/2008 | 10:10AM | UKREG | Rule 8.3- Oxford Biomedica PLC
RNS Number : 9189B
State Street Global Advisors
22 August 2008
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the City Code on Takeovers & Mergers)
1. KEY INFORMATION
Name of Person State Street
Dealing (Note 1) Global... More...>> |
| 08/21/2008 | 4:26AM | UKREG | EPT Disclosure
RNS Number : 7846B
Cazenove
21 August 2008
FORM 38.5(a)
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITH RECOGNISED INTERMEDIARY STATUS
DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(a) of the Takeover Code)
1. KEY INFORMATION
Name of exempt principal trader... More...>> |
| 08/20/2008 | 9:40AM | UKREG | Rule 8.3 - OXFORD BIOMEDICA
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the City Code on Takeovers and Mergers)
1. KEY INFORMATION
Name of person dealing BARCLAYS PLC
(Note 1)
Company dealt in... More...>> |
| 08/20/2008 | 6:49AM | TFNF | BRIEF-Genethera considering options for Oxford Biomedica
LONDON, Aug 20 (Reuters) - Oxford Biomedica Plc.:
* Genethera says is currently considering its options in respect of a
potential
acquisition of Oxford Biomedica PLC
* Any offer, if made, will be a securities exchange offer.
((London Equities Newsroom; +44 20 7542 7717))
TFN.newsdesk@thomson.com
jag
COPYRIGHT
Copyright... More...>> |
| 08/20/2008 | 6:27AM | UKREG | GENETHERA POTENTIAL OFFER FOR OXFORD BIOMEDICA
RNS Number : 7078B
Genethera Inc.
20 August 2008
GENETHERA POTENTIAL OFFER FOR OXFORD BIOMEDICA
WHEAT RIDGE, CO, August 20, 2008 - Further to the announcement released by Oxford Biomedica Plc on August 15, 2008, GeneThera, Inc.
(Pink Sheets: GTHR), would like to announce that is currently considering... More...>> |
| 08/18/2008 | 6:01AM | UKREG | EPT Disclosure
RNS Number : 5153B
Cazenove
18 August 2008
FORM 38.5(a)
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITH RECOGNISED INTERMEDIARY STATUS
DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(a) of the Takeover Code)
1. KEY INFORMATION
Name of exempt principal trader... More...>> |
| 08/18/2008 | 5:21AM | UKREG | Notification of Major Interest in Shares
RNS Number : 5112B
Oxford Biomedica PLC
18 August 2008
For Immediate Release 18 August 2008
Oxford BioMedica Plc
TR-1: Notifications of Major Interests in Shares
Oxford BioMedica Plc
1. Identity of the issuer or the underlying issuer... More...>> |
| 08/15/2008 | 8:19AM | UKREG | Rule 2.10 Announcement
RNS Number : 4451B
Oxford Biomedica PLC
15 August 2008
For Immediate Release 15 August 2008
Oxford BioMedica Plc
("Oxford BioMedica")
Rule 2.10 Announcement
In accordance with Rule 2.10 of the Takeover Code, Oxford BioMedica confirms that at close of business on 14 August... More...>> |
| 08/15/2008 | 7:09AM | TFNF | Oxford Biomedica confirms it rejected bid from GeneThera
Gene therapy company Oxford Biomedica Plc.
confirmed that it has rejected U.S.-based GeneThera's revised proposal for an
all-share offer for the company.
The company said it initially rejected GeneThera's approach on July 31, as
it felt that GeneThera is not a credible bidder for the company. However, on
Aug... More...>> |
| 08/15/2008 | 6:38AM | UKREG | Rejection of GeneThera's indicative approach
RNS Number : 4315B
Oxford Biomedica PLC
15 August 2008
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE 15 AUGUST 2008... More...>> |
| 07/28/2008 | 2:01AM | UKREG | Board Appointment
RNS Number : 9433Z
Oxford Biomedica PLC
28 July 2008
For Immediate Release 28 JULY 2008
OXFORD BIOMEDICA APPOINTS JOHN DAWSON AS NON-EXECUTIVE DIRECTOR
Oxford, UK - 28 July 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that John Dawson BSc (Hons),
ACA... More...>> |
| 07/15/2008 | 11:13AM | UKREG | TROVAX Phase III TRIST Study
RNS Number : 1335Z
Oxford Biomedica PLC
15 July 2008
FOR IMMEDIATE RELEASE 15 JULY 2008
OXFORD BIOMEDICA REPORTS FURTHER DATA FROM INTERIM REVIEW OF TROVAX® PHASE III TRIST STUDY
Oxford, UK - 15 July 2008: Oxford BioMedica (LSE: OXB), announced that it has written to all investigators... More...>> |
| 07/14/2008 | 4:49AM | TFNF | Oxford Biomedica says Phase III QUASAR trial for Trovax to progress
Oxford BioMedica Plc. said the Independent
Oncology Clinical Trials Office (OCTO) remains committed to the QUASAR V Phase
III trial for TroVax in colorectal cancer although the trial, along with the
rest of the Trovax programme, is under review by Oxford and its partner
Sanofi-Aventis after recent clinical setbacks... More...>> |
| 07/14/2008 | 3:48AM | UKREG | TroVax QUASAR Trial
RNS Number : 9707Y
Oxford Biomedica PLC
14 July 2008
FOR IMMEDIATE RELEASE 14 JULY 2008
Oxford BioMedica
OXFORD BIOMEDICA RECEIVES COMMITMENT FOR INDEPENDENT PHASE III TRIAL OF TROVAX® IN ADJUVANT COLORECTAL CANCER
Oxford, UK - 14 July 2008: Oxford BioMedica (LSE: OXB... More...>> |
| 07/11/2008 | 4:33AM | TFNF | Oxford Biomedica's TroVax phase III renal cancer test will not meet goals UPDATE
(Adds company comments, analyst reaction, share price)
Oxford Biomedica Plc's cancer vaccination
TroVax, the group's lead drug, will not meet its defined goals in a late-stage
study for renal cancer, according to a key review board.
While the trial will continue, the Drug Safety Monitoring Board has... More...>> |
| 07/11/2008 | 4:04AM | TFNF | UK smallcap opening - Oxford Biomedica slumps on Trovax disappointment
Top small cap faller was Oxford Biomedica,
which slumped 11.01 pence to just 7.49 pence following news that cancer
vaccination TroVax will not meet its defined goals in a late stage study for
renal cancer, according to a key review board.
While the trial will continue, the Drug Safety Monitoring Board has... More...>> |
| 07/11/2008 | 2:27AM | TFNF | Oxford Biomedica's phase III trial for cancer jab Trovax 'will not meet goals'
Oxford Biomedica Plc's cancer vaccination
TroVax will not meet its defined goals in a late stage study for renal cancer,
according to a key review board.
While the trial will continue, the Drug Safety Monitoring Board has ruled
that there should be no more vaccinations administered.
Chief executive... More...>> |
| 07/11/2008 | 2:00AM | UKREG | RECOMMENDATION FOR TROVAX® PHASE III TRIST STUDY
RNS Number : 8486Y
Oxford Biomedica PLC
11 July 2008
For Immediate Release 11 JULY 2008
OXFORD BIOMEDICA ANNOUNCES DATA SAFETY MONITORING BOARD RECOMMENDATION FOR TROVAX® PHASE III TRIST STUDY
Oxford, UK - 11 July 2008: Oxford BioMedica (LSE:... More...>> |
| 07/01/2008 | 5:40AM | TFNF | Oxford Biomedica says Bavarian Nordic's U.S. litigation without merit
Oxford BioMedica Plc. said Bavarian Nordic's
patent infringement suit in a U.S. court against Oxford BioMedica over three
patents relating to Modified Vaccinia Ankara (MVA) is without merit.
The gene therapy company said it is confident in its position, is fully
prepared to oppose the action vigorously... More...>> |